Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology

Antibody–drug conjugates (ADCs) are important molecular entities in the treatment of cancer. These conjugates combine the target specificity of monoclonal antibodies with the potent anti-cancer activity of small-molecule therapeutics. The complex structure of ADCs poses unique challenges to characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Stephanie N., Li, Chunze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110483/
https://www.ncbi.nlm.nih.gov/pubmed/33792763
http://dx.doi.org/10.1007/s00280-021-04250-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110483/
https://www.ncbi.nlm.nih.gov/pubmed/33792763
http://dx.doi.org/10.1007/s00280-021-04250-0

Ejemplares similares